BioSpace News Archive

The U.S. Food and Drug Administration gave the green light to Aurinia’s Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen for LN.

Merck announced that it is going to stop developing its two COVID-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.

Roche announced topline data from two identical Phase III trials, TENAYA and LUCERNE, of faricimab in neovascular or “wet” age-related macular degeneration (nAMD).

As the industry leader in translating RNA interference (RNAi) into innovative medicines for debilitating diseases, Alnylam employs over 1,400 people worldwide. The company boasts a robust pipeline of therapeutics for genetic, cardio-metabolic, infectious and CNS diseases with four registered products. With this kind of groundbreaking work, it comes as no surprise that they spend a lot of time looking for the right fit – and insist on the importance of the right mutual fit.

Part of the difficulty of treating breast cancer is the genomic variability of the patient population, as well as the different forms the cancer can take.

Alexion Pharmaceuticals is a global biopharmaceutical company developing life-transforming therapies for patients with the rarest of diseases. So, it stands to reason that they are also looking for a rare combination in their employees. BioSpace we spoke with Alexion’s Head of Talent Acquisition, Matt McSherry, to find out just what those key ingredients are.

cellvie Inc., the leader in Therapeutic Mitochondria Transfer (TMT) and a Harvard University spin-off, closes a $5M round to advance its product pipeline, including a first application in rejuvenation.

A study from researchers at Monash University in Melbourne has identified two molecules in the gut microbiome that can protect against asthma and may possibly reduce the severity of an asthma attack.

Industry-leading biotech CSL is leveraging its integrated global portfolio to bring urgently needed therapeutic COVID-19 treatments to patients around the world.

If you know Roivant as a brand you might be familiar with Vivek Ramaswamy too. Recently, he stepped down as CEO and became Executive Chairman. Let’s know more.